Advanced search
1 file | 446.07 KB

The new Sulindac derivative IND 12 reverses Ras-induced cell transformation

(2002) CANCER RESEARCH. 62(6). p.1718-1723
Author
Organization
Abstract
The nonsteroidal anti-inflammatory drug Sulindac has chemopreventive and antitumorigenic properties. Its metabolites induce apoptosis and inhibit signaling pathways critical for malignant transformation, including the Ras pathway. Here we show that the new Sulindac derivative IND 12 reverses the phenotype of Ras-transformed MDCK-f3 cells and restores an untransformed epithelioid morphology characterized by growth in monolayers with regular cell-cell adhesions. Moreover, IND 12 treatment induces the expression at membranes of the cell adhesion protein E-cadherin and increases the level of the E-cadherin-bound beta-catenin. As a consequence, IND 12-treated MDCK-f3 cells lose their invasion capacity and regain the ability to aggregate. In the presence of IND 12, MDCK-f3 cells show regenerated expression and activity ratios of the small GTPases Rac and Rho normally found in untransformed MDCK cells. Strikingly, IND 12 treatment decreases the levels of phosphorylated mitogen-activated protein kinases, which are downstream substrates of the Ras-regulated Raf/mitogen-activated protein kinase pathway, and the level of Ras-induced activation of gene expression. Our findings identify a novel drug with high potential in cancer therapy by targeting Ras-induced cell transformation.
Keywords
KINASE, DIFFERENTIATION, FAMILIAL ADENOMATOUS POLYPOSIS, COLON-CANCER CELLS, EPITHELIAL-CELLS, COLORECTAL-CANCER, APOPTOSIS, INVASION, CARCINOGENESIS, ADHESION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 446.07 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Karaguni, Ioanna-Maria, Peter Herter, Philip Debruyne, Slava Chtarbova, Alice Kasprzynski, Ulrike Herbrand, M-Reza Ahmadian, et al. 2002. “The New Sulindac Derivative IND 12 Reverses Ras-induced Cell Transformation.” Cancer Research 62 (6): 1718–1723.
APA
Karaguni, I.-M., Herter, P., Debruyne, P., Chtarbova, S., Kasprzynski, A., Herbrand, U., Ahmadian, M.-R., et al. (2002). The new Sulindac derivative IND 12 reverses Ras-induced cell transformation. CANCER RESEARCH, 62(6), 1718–1723.
Vancouver
1.
Karaguni I-M, Herter P, Debruyne P, Chtarbova S, Kasprzynski A, Herbrand U, et al. The new Sulindac derivative IND 12 reverses Ras-induced cell transformation. CANCER RESEARCH. 2002;62(6):1718–23.
MLA
Karaguni, Ioanna-Maria, Peter Herter, Philip Debruyne, et al. “The New Sulindac Derivative IND 12 Reverses Ras-induced Cell Transformation.” CANCER RESEARCH 62.6 (2002): 1718–1723. Print.
@article{151771,
  abstract     = {The nonsteroidal anti-inflammatory drug Sulindac has chemopreventive and antitumorigenic properties. Its metabolites induce apoptosis and inhibit signaling pathways critical for malignant transformation, including the Ras pathway. Here we show that the new Sulindac derivative IND 12 reverses the phenotype of Ras-transformed MDCK-f3 cells and restores an untransformed epithelioid morphology characterized by growth in monolayers with regular cell-cell adhesions. Moreover, IND 12 treatment induces the expression at membranes of the cell adhesion protein E-cadherin and increases the level of the E-cadherin-bound beta-catenin. As a consequence, IND 12-treated MDCK-f3 cells lose their invasion capacity and regain the ability to aggregate. In the presence of IND 12, MDCK-f3 cells show regenerated expression and activity ratios of the small GTPases Rac and Rho normally found in untransformed MDCK cells. Strikingly, IND 12 treatment decreases the levels of phosphorylated mitogen-activated protein kinases, which are downstream substrates of the Ras-regulated Raf/mitogen-activated protein kinase pathway, and the level of Ras-induced activation of gene expression. Our findings identify a novel drug with high potential in cancer therapy by targeting Ras-induced cell transformation.},
  author       = {Karaguni, Ioanna-Maria and Herter, Peter and Debruyne, Philip and Chtarbova, Slava and Kasprzynski, Alice and Herbrand, Ulrike and Ahmadian, M-Reza and Gl{\"u}senkamp, Karl-Heinz and Winde, G{\"u}nther and Mareel, Marcus and M{\"o}r{\"o}y, Tarik and M{\"u}ller, Oliver},
  issn         = {0008-5472},
  journal      = {CANCER RESEARCH},
  keyword      = {KINASE,DIFFERENTIATION,FAMILIAL ADENOMATOUS POLYPOSIS,COLON-CANCER CELLS,EPITHELIAL-CELLS,COLORECTAL-CANCER,APOPTOSIS,INVASION,CARCINOGENESIS,ADHESION},
  language     = {eng},
  number       = {6},
  pages        = {1718--1723},
  title        = {The new Sulindac derivative IND 12 reverses Ras-induced cell transformation},
  url          = {http://cancerres.aacrjournals.org/content/62/6/1718},
  volume       = {62},
  year         = {2002},
}

Web of Science
Times cited: